Table 1:
Preoperative patient characteristics
| Variable | BPA group | non-BPA group | P-value |
|---|---|---|---|
| n | 21 | 37 | |
| Age, years | 59 [52.0, 71.5] | 63 [52.0, 72.0] | 0.710 |
| Females, % (n) | 61.9 (13) | 64.9 (24) | 0.822 |
| Body mass index ≥30 kg/m2, % (n) | 23.8 (5) | 16.2 (6) | 0.478 |
| Hypertension | 28.6 (6) | 48.7 (18) | 0.136 |
| Dyslipidaemia | 23.8 (5) | 13.5 (5) | 0.319 |
| Serum creatinine ≥1.5 mg/dl, % (n) | 4.8 (1) | 5.4 (2) | 1.000 |
| Haemodialysis | 0 | 2.7 (1) | 1.000 |
| Haemoglobin A1c ≥7.0%, % (n) | 4.8 (1) | 0 | 0.362 |
| Atrial fibrillation, % (n) | 0 | 5.4 (2) | 0.530 |
| Peripheral vascular disease, % (n) | 0 | 5.4 (2) | 0.530 |
| Depression or schizophrenia, % (n) | 4.8 (1) | 13.5 (5) | 0.293 |
| History of cerebral infarction, % (n) | 4.8 (1) | 10.8 (4) | 0.430 |
| Steroid use | 0 | 2.7 (1) | 1.000 |
| Thrombotic predisposition, % (n) | 23.8 (5) | 16.2 (6) | 0.478 |
| Current smoker, % (n) | 19.1 (4) | 8.1 (3) | 0.241 |
| Former smoker, % (n) | 23.8 (5) | 29.7 (11) | 0.628 |
| Inotropic agent, % (n) | 14.3 (3) | 2.7 (1) | 0.130 |
| NYHA/WHO functional class | |||
| II, % (n) | 38.1 (8) | 27.0 (10) | 0.382 |
| III, % (n) | 47.6 (10) | 67.6 (25) | 0.252 |
| IV, % (n) | 14.3 (3) | 5.4 (2) | 0.341 |
| Supportive therapy | |||
| Oral PAH-targeted MT | 95.2 (20) | 83.8 (31) | 0.198 |
| Riociguat, % (n) | 85.7 (18) | 62.2 (23) | 0.058 |
| Intravenous PAH-targeted MT | |||
| Epoprostenol | 0 | 24.3 (9) | 0.020 |
| Home oxygen therapy, % (n) | 85.7 (18) | 78.4 (29) | 0.493 |
Data are presented as medians [interquartile range].
BPA: balloon pulmonary angioplasty; MT: medical treatment; NYHA/WHO: New York Heart Association/World Health Organization; PAH: pulmonary arterial hypertension.